ATE451389T1 - Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen - Google Patents

Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen

Info

Publication number
ATE451389T1
ATE451389T1 AT99958854T AT99958854T ATE451389T1 AT E451389 T1 ATE451389 T1 AT E451389T1 AT 99958854 T AT99958854 T AT 99958854T AT 99958854 T AT99958854 T AT 99958854T AT E451389 T1 ATE451389 T1 AT E451389T1
Authority
AT
Austria
Prior art keywords
platele
growth factor
derived growth
dna coding
pdgf
Prior art date
Application number
AT99958854T
Other languages
English (en)
Inventor
Ulf Eriksson
Karin Aase
Annica Ponten
Xuri Li
Marko Uutela
Kari Alitalo
Arne Oestman
Carl-Henrik Heldin
Original Assignee
Ludwig Inst Cancer Res
Licentia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Licentia Ltd filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE451389T1 publication Critical patent/ATE451389T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
AT99958854T 1998-11-10 1999-11-10 Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen ATE451389T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10785298P 1998-11-10 1998-11-10
US11399798P 1998-12-28 1998-12-28
US15060499P 1999-08-26 1999-08-26
US15710899P 1999-10-04 1999-10-04
US15775699P 1999-10-05 1999-10-05
PCT/US1999/026462 WO2000027879A1 (en) 1998-11-10 1999-11-10 Platelet-derived growth factor d, dna coding therefor, and uses thereof

Publications (1)

Publication Number Publication Date
ATE451389T1 true ATE451389T1 (de) 2009-12-15

Family

ID=27537197

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99958854T ATE451389T1 (de) 1998-11-10 1999-11-10 Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen
AT09177387T ATE556090T1 (de) 1998-11-10 1999-11-10 Verkürzter, von blutplättchen abstammender wachstumsfaktor d, dafür kodierendes dns und deren verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT09177387T ATE556090T1 (de) 1998-11-10 1999-11-10 Verkürzter, von blutplättchen abstammender wachstumsfaktor d, dafür kodierendes dns und deren verwendung

Country Status (12)

Country Link
US (1) US6706687B1 (de)
EP (2) EP1129110B1 (de)
JP (1) JP2002534061A (de)
CN (1) CN1261453C (de)
AT (2) ATE451389T1 (de)
AU (1) AU770899B2 (de)
CA (1) CA2349951A1 (de)
DE (1) DE69941791D1 (de)
DK (1) DK1129110T3 (de)
ES (1) ES2336731T3 (de)
NZ (1) NZ511379A (de)
WO (1) WO2000027879A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468543B1 (en) * 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
JP2002542825A (ja) * 1999-05-03 2002-12-17 ザイモジェネティクス,インコーポレイティド 増殖因子同族体zvegf4
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
AU7868000A (en) * 1999-10-07 2001-05-10 Curagen Corporation Growth factor polypeptides and nucleic acids encoding same
AU2001272902A1 (en) * 2000-05-19 2001-12-03 Eli Lilly And Company Treating musculoskeletal disorders using lp85 and analogs thereof
CA2427143A1 (en) * 2000-10-30 2002-08-08 Zymogenetics, Inc. Compositions and methods for improving kidney function
WO2002059618A2 (en) * 2000-11-16 2002-08-01 Curagen Corporation Growth factor polypeptides and nucleic acids encoding same
AU2002337920A1 (en) * 2001-10-19 2003-04-28 Zymogenetics, Inc. Dimerized growth factor and materials and methods for producing it
US7135174B2 (en) * 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
EP1483298A4 (de) 2002-02-11 2007-03-14 Zymogenetics Inc Materialien und verfahren zur herstellung dimerer wachstumsfaktoren
US20040141969A1 (en) * 2002-09-16 2004-07-22 Juergen Floege Method for the treatment of nephritis using anti-PDGF-DD antibodies
US20030100502A1 (en) * 2002-10-23 2003-05-29 Beals John Michael Treating musculoskeletal disorders using lp85 and analogs thereof
US20050191286A1 (en) * 2004-02-09 2005-09-01 Gandy James B. Lyophilized platelet rich plasma for the use in wound healing (chronic or acute) and bone or tissue grafts or repair
US20060024302A1 (en) 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
EP1773373A4 (de) * 2004-03-08 2010-11-17 Ludwig Inst Cancer Res Verfahren zur modulierung, regulierung und/oder stabilisierung von angiogenese
US20060004189A1 (en) * 2004-07-02 2006-01-05 James Gandy Compositions for treating wounds and processes for their preparation
US20060142198A1 (en) * 2004-07-02 2006-06-29 Wound Care Partners Llc Compositions for treating wounds and processes for their preparation
EP1885888A4 (de) * 2005-05-10 2010-05-05 Ludwig Inst Cancer Res Verfahren und zusammensetzungen zur aktivierung und hemmung von pdgf-d
ES2363758T3 (es) 2005-08-15 2011-08-16 Vegenics Pty Ltd Vegf y pdgf modificados con propiedades angiogénicas mejoradas.
ES2429225T3 (es) 2006-05-17 2013-11-13 The Ludwig Institute For Cancer Research Anticuerpos anti VEGF-B para tratamiento o profilaxis de diabetes de tipo II o síndrome metabólico
WO2010090523A1 (en) * 2009-02-06 2010-08-12 Pepscan Systems B.V. Truncated cystine-knot proteins
KR101451340B1 (ko) * 2012-08-02 2014-10-15 (주)애드바이오텍 모발 생장 촉진용 조성물
CN103469672A (zh) * 2013-09-07 2013-12-25 郴州四方立投资有限公司 一种用于造纸行业的硅灰石长纤维的制备方法
CA2991301A1 (en) * 2015-07-13 2017-01-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
CN110590930B (zh) * 2018-06-13 2023-03-31 四川好医生攀西药业有限责任公司 美洲大蠊生长因子pdgf在制备损伤修复药物中的应用
CN111487398B (zh) * 2019-01-25 2022-11-11 四川大学华西医院 血管瘤治疗的生物标记物
CN115612661B (zh) * 2021-07-14 2026-02-13 中山大学中山眼科中心 Pdgf-d在调控干细胞增殖和/或分化中的应用
CN114957439B (zh) * 2022-05-31 2023-11-28 新疆畜牧科学院生物技术研究所(新疆畜牧科学院中国-澳大利亚绵羊育种研究中心) 绵羊pdgfd、编码pdgfd核酸及其重组慢病毒、宿主细胞与应用
CN119997965A (zh) * 2022-06-29 2025-05-13 天津大学 Pdgf-d前结构域及其变体和融合体
KR20250040765A (ko) * 2023-09-15 2025-03-25 (주)케어젠 펩타이드를 유효성분으로 하는 발모 촉진 또는 탈모증의 억제, 예방 또는 개선용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4228457A1 (de) * 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
DK0751992T3 (da) 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5607918A (en) 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
WO1996027007A1 (en) 1995-03-02 1996-09-06 Amrad Operations Pty. Ltd. A novel growth factor and a genetic sequence encoding same
CA2224002A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3
EP0956339B1 (de) 1996-08-23 2005-10-12 Ludwig Institute For Cancer Research Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
DE69939330D1 (de) * 1998-12-07 2008-09-25 Zymogenetics Inc Wachstumsfaktor-homologe zvegf-3
JP2002542825A (ja) * 1999-05-03 2002-12-17 ザイモジェネティクス,インコーポレイティド 増殖因子同族体zvegf4

Also Published As

Publication number Publication date
AU770899B2 (en) 2004-03-04
JP2002534061A (ja) 2002-10-15
CN1325407A (zh) 2001-12-05
EP1129110A4 (de) 2004-08-04
EP1129110A1 (de) 2001-09-05
CN1261453C (zh) 2006-06-28
AU1613600A (en) 2000-05-29
ES2336731T3 (es) 2010-04-15
DE69941791D1 (de) 2010-01-21
ATE556090T1 (de) 2012-05-15
EP1129110B1 (de) 2009-12-09
EP2151454B1 (de) 2012-05-02
DK1129110T3 (da) 2010-04-06
EP2151454A3 (de) 2010-02-17
US6706687B1 (en) 2004-03-16
NZ511379A (en) 2003-06-30
CA2349951A1 (en) 2000-05-18
WO2000027879A1 (en) 2000-05-18
EP2151454A2 (de) 2010-02-10

Similar Documents

Publication Publication Date Title
ATE556090T1 (de) Verkürzter, von blutplättchen abstammender wachstumsfaktor d, dafür kodierendes dns und deren verwendung
BRPI0013391B8 (pt) uso de polipeptídeos bcma na preparação de uma composição farmacêutica para tratar uma doença autoimune ou um distúrbio linfoproliferativo de célula b
DE3280400D1 (de) Oligonukleotides heilmittel und dessen herstellungsverfahren.
ATE376054T1 (de) Diacylglyzerin o-acyltransferase
ATE408699T1 (de) Verabreichung von nukleinsäuren und proteinen an zellen
DE59913833D1 (de) Strukturprotein von aav, seine herstellung und verwendung
EP2248892A3 (de) Fusionskonstruktionen und deren Verwendung zur Herstellung von Antikörpern mit erhöhter Fc-Rezeptor-Bindeaffinität und Effektorfunktion
DK1095140T3 (da) Neurotrofe faktorer
DE3650751D1 (de) Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung
ATE507828T1 (de) Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung
EE200300100A (et) Polüpeptiid, selle kodeerivat nukleotiidjärjestust sisaldav nukleiinhape, vektor ja peremeesrakk, meetod polüpeptiidi valmistamiseks ning farmatseutiline kompositsioon
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
FI962247L (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DE69939426D1 (de) Diacylglycerin o-acyltransferase
ATE130869T1 (de) Protein mit der aktivität vom typ von cytokin, dafür kodierende rekombinante dns, transformierte zellen und mikroorganismen.
WO2004046365A3 (en) Interferon-alpha polypeptides and conjugates
DE69839582D1 (de) Neues polypeptid, dafür kodierende dna und deren verwendungen
DE59900546D1 (de) Pseudoböhmit und gamma al2o3 enthaltender trägerkatalysator, dessen herstellung und dessen verwendung zur herstellung von 1,2-dichlorethan
FI972170A7 (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, n äitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
DE3881691D1 (de) Polydeoxyribonukleotide, pharmazeutische zusammensetzungen, verwendung und herstellung von polydeoxyribonukleotiden.
DK560686D0 (da) Fremgangsmaade til fremstilling af proteiner ved hjaelp af vaertsorganismer, fortrinsvis maelkesyrebakterier
ATE286509T1 (de) Interferon alpha/beta bindendes protein, seine herstellung und anwendung
ES2059801T3 (es) Nuevas linfoquinas, secuencias de adn que codifican para estas linfoquinas, y composiciones farmaceuticas conteniendo estas linfoquinas.
DE3671603D1 (de) Verfahren zur zucht von babesia canis, verwendung zur herstellung von antigenen und impfstoffen und antigene und impfstoffe gegen piroplasmose.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1129110

Country of ref document: EP